GlassScriptPhysician profile
Bryan W Ghiloni
NPI 1760429914
$2,173.00
in general payments reported to CMS, 2019-2025
25 companies · $540 in 2025
The $540 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $216 · 2023: $375 · 2024: $1,042 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $637.22 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $381.94 | 2022-2025 | |
| Novo Nordisk INC | $199.37 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $165.83 | 2024-2025 | Airsupra, Farxiga |
| Procept Biorobotics Corporation | $122.10 | 2024 | Aquabeam System |
| Corium, LLC | $104.56 | 2023-2025 | Azstarys |
| Pfizer INC. | $83.55 | 2023-2024 | |
| Dexcom, INC. | $57.07 | 2023-2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.40 | 2025 | Caplyta |
| Lilly USA, LLC | $52.75 | 2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $34.34 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $33.57 | 2024-2025 | Dificid, Capvaxive, Gardasil 9 |
| Axsome Therapeutics, INC. | $32.12 | 2025 | Symbravo |
| Astellas Pharma US INC | $30.45 | 2025 | Veozah |
| Globus Medical, INC. | $28.78 | 2025 | Senza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $21.81 | 2025 | |
| Exact Sciences Corporation | $20.54 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $18.41 | 2025 | Camzyos |
| Ani Pharmaceuticals, INC. | $17.18 | 2023 | Purified Cortrophin Gel |
| Neos Therapeutics, LP | $16.94 | 2024 | Adzenys Xr-Odt |
| Gilead Sciences, INC. | $15.52 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.07 | 2023 | |
| Phathom Pharmaceuticals, INC. | $14.11 | 2024 | Voquezna |
| Tris Pharma INC | $13.37 | 2023 | Dyanavel Xr |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Ghiloni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.